"Designing Growth Strategies is in our DNA"

Nebulizer Market Size, Share, and COVID-19 Impact Analysis, By Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), By Modality (Table-top, and Portable), By End-user (Hospitals, Clinics, and Homecare Settings), and Regional Forecasts, 2022-2029

Region : Global | Format: PDF | Report ID: FBI100707

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global nebulizer market size was valued at USD 833.6 million in 2021. The market is projected to grow from USD 863.4 million in 2022 to USD 1,202.5 million by 2029, exhibiting a CAGR of 4.8% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with nebulizer experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. Based on our analysis, the global nebulizer market exhibited a higher growth of 5.2% in 2020 as compared to 2019.


A nebulizer is a drug delivery device that enables medication administration in the form of a mist into the lungs. These devices pump pressurized air through the liquid to form a fine mist, breathed in through a mouthpiece or mask. These machines are designed to treat asthma, asthma cystic fibrosis, COPD, and other respiratory disorders.


The increasing incidence of respiratory disorders globally and the rising geriatric population are likely to fuel the market growth during the forecast period. Rising demand for innovative respiratory drug delivery devices and the rapid adoption of these devices among the patient population is likely to drive their usage during the forecast period.  


COVID-19 IMPACT


Critical Shortage of Ventilators and Meter Dose Inhalers Increased the Demand for Nebulizer Devices during COVID-19 Pandemic


The COVID-19 pandemic positively impacted the demand for nebulizers during the forecast period. The outbreak of the COVID-19 pandemic across the globe accelerated the demand for devices to efficiently control the spread of this respiratory infection. Also, several key players exhibited strong growth during the pandemic. For instance, in 2021, the connected care business segment of Koninklijke Philips N.V. generated a revenue of USD 6,628.6 million in 2020 and witnessed a growth of 19.1%, as compared to USD 5,564.3 million in 2019. The segment showed a decline of 17.5% in 2021 in terms of revenue, which was USD 5,467.9 million compared to 2020.


As coronavirus cases accelerated, many countries faced a critical shortage of ventilators and meter dose inhalers. The shortage led to increased demand for the equipment used for management of critical care conditions such as ventilators, pulse oximeters, and others. This shortage of ventilators forced healthcare professionals to use other respiratory devices such as nebulizers, Continuous Positive Airway Pressure (CPAP), and oxygen concentrators. For instance, in March 2020, according to the American College of Allergy, Asthma & Immunology in the U.S. the prescription rate of nebulizers increased during the pandemic due to shortage of metered dose inhalers.


Also, many pharmaceutical companies emphasized the development of effective therapies for the treatment of COVID-19 that can be administered through nebulizers.



  • For instance, in May 2021, Vectura Group plc collaborated with Inspira Pharmaceuticals Limited and entered into an agreement for the development of an inhaled formulation that can be used for the treatment of COVID-19. Vectura will test IPX formulation delivery to lungs through Vectura’s FOX vibrating mesh nebulizer through this agreement.

  • Furthermore, in December 2020, Ampio Pharmaceuticals Inc announced that it had started open enrollment for its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients. The Ampion in the clinical trial is administered using a handheld nebulizer to deliver the drug directly into the lungs. The generation of positive responses from the clinical study is anticipated to propel the market growth. Moreover, suppose medical device companies strongly emphasize the development of advanced devices in this segment that reduce the generation of aerosols. In that case, there is a more substantial possibility of an upsurge in the growth of this market amid the coronavirus pandemic.


LATEST TRENDS


Request a Free sample to learn more about this report.


Rising Innovation by Market Players is Leading to a Preferential Shift toward Vibrating Mesh Nebulizers 


Growing innovations by market players with the development of technologically advanced devices, dispensing medication at a consistent particle size, and making the overall administration experience comfortable have led to increased utilization of vibrating mesh nebulizers. Thus, easy and comfortable use of this device is likely to contribute to the increase in the adoption of these systems.



  • In June 2020, Respira Technologies, Inc. launched the RespiRx nebulizer in the market. This new drug delivery platform is an ultra-portable handheld Vibrating Mesh Nebulizer (VMN) intended for the local and systemic treatment of patients.


Such innovative devices are likely to accelerate the demand for these portable devices rapidly. Rising awareness among healthcare providers about innovative products and the increase in collaborations among players to extend their market reach are anticipated to accelerate the market growth


DRIVING FACTORS


Increasing Incidence of Respiratory Disorders to Propel Market Growth


Asthma, Chronic Obstructive Pulmonary Disorder (COPD), and other respiratory conditions are exerting a substantial economic burden on the healthcare systems of various countries globally. For instance, according to the statistics published by the Asthma and Allergy Foundation of America in April 2022, approximately 25.0 million people in the U.S. have asthma. Similarly, according to an article published by Greater London Authority in July 2021, around 337,500 people in London suffered from asthma attacks, with poor air quality being the reason.  There has been a rise in the prevalence of these conditions, owing to various factors, including an increase in the smoking population, poor air quality, and so on.



  • For instance, according to the data published by the World Health Organization (WHO), in 2022, there will be around 262.0 million people suffering from asthma in the year 2019.

  • In 2021, according to an article published by the Physiopedia, there will be around 65.0 million people suffering from chronic obstructive pulmonary disease (COPD).


According to the Global Strategy for Diagnosis, Management, and Prevention of COPD report, the European Union spends around 6% of its total healthcare budget on managing respiratory disorders (direct costs) each year. Also, according to the report, COPD accounts for roughly 60% of the EU's total expenditure on respiratory diseases each year.


In emerging countries, the prevalence is gradually increasing, which is resulting in a large number of patients suffering from respiratory disorders. Various government initiatives toward promoting early diagnosis and treatment are leading to an increasing number of patients undergoing treatment. Furthermore, increasing introduction of new products in the market, including nebulization devices, has been pivotal in driving the adoption of these devices. For instance, in 2020, Omron Healthcare introduced the ‘OMRON NE C106’, a cost-effective and all-age-group compatible nebulization device in India.


Growing Demand for Home Healthcare Devices to Drive Market Growth


The rising cost of healthcare services and hospital stays has led to a preferential shift of patient treatment towards homecare settings. The increasing cost of the hospital stays for treating respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma and others emphasizes patients to take treatment in the homecare setting.



  • For instance, in 2021, MDinteractive published an article that stated in the U.S., the hospitalization cost for a COPD inpatient is around USD 19,000 annually.

  • Also, community homecare published an article stating that the average daily cost of a hospital stay in the U.S. for a chronic condition such as diabetes, heart and circulatory diseases, chronic obstructive pulmonary diseases, and others is around USD 6,200 as compared to USD 135 per visit for home healthcare cost.  


This factor led to an increase in the adoption of breathable medical devices for home healthcare. Thus, the growing demand for effective inhaled drug delivery devices and the promotion of respiratory care devices for home use by many healthcare organizations are likely to boost the growth of this market during the forecast period.


RESTRAINING FACTORS


Risk of Disease Transmission & Availability of Alternate Treatment Options to Limit the Product Adoption 


There are concerns raised on the safety profile of respiratory devices for transmission of the infection. The factors such as the risk of infection transfer from the tubing of nebulizers to the patient's lungs or the transmission of infection from the unsterile chambers of the devices are further limiting the recommendations given by the healthcare professionals for the use of these devices.



  • For instance, according to an article published by the Canadian Medical Association Journal in March 2020, the risk of transmission of infection increased during nebulizer treatments due to its potential to generate a high volume of respiratory aerosols, which increases the risk of spreading the disease.


Therefore, due to these factors in recent years, some centers have shifted from using nebulizer to metered dose inhalers (pMDI) with valved holding chambers. The metered dose inhalers are small, portable, and easy to carry, offering clinical and operational benefits in the treatment of asthma.


Cost and the increasing availability of alternate options for treatment are also limiting the growth of the segment. The demand for nebulizer is likely to face competition with a growing acceptance of substitute devices for treating respiratory disorders by patients. There is an increasing preference from healthcare providers for inhalers, including metered-dose inhalers for asthma treatment. The clinical and operational benefits of MDIs in treating asthma and the lower cost of these devices have witnessed a preferential shift of patients from nebulization devices to inhalers. Moreover, limited reimbursement policies in developing economies and the higher costs of mesh nebulizers will likely hamper the nebulizer market growth during the forecast period.


SEGMENTATION


By Type Analysis


To know how our report can help streamline your business, Speak to Analyst


Clinically Approved Advanced Product Introduction is Leading to the Dominance of Jet Nebulizer Segment 


Based on type, the market is segmented into jet nebulizer, mesh nebulizer, and ultrasonic nebulizer.


Nebulization devices based on jet technology for delivering aerosolized medications have been used traditionally. The clinically proven technological advantages of jet devices and comparatively lower costs have been instrumental in higher adoption of these devices globally. Furthermore, the emergence of domestic manufacturers offering new and low-cost devices in this segment, especially in emerging countries, is fueling segmental growth.


The mesh nebulizer segment is expected to register a comparatively higher CAGR during the forecast period. Technological superiorities of mesh technology in aerosol drug delivery, along with R&D advances made by the manufacturers, have led to a growing preference for these devices by patients and healthcare providers in developed countries. Also, the approval from the regulatory authorities of the developed countries contributes to the growth of the segment. For instance, in July 2021, HCmed received approval from the U.S. FDA for Pulmogine, a portable vibrating mesh nebulizer designed to deliver medication directly into the airways. However, comparatively lower penetration of these devices in emerging countries owing to high cost has limited the segment’s growth to a certain extent.


The ultrasonic nebulizer segment is anticipated to have steady growth. Limitations offered by ultrasound devices to aerosolized viscous solutions and drugs, along with other clinical and technological limitations, have witnessed limited preference for these devices, especially in emerging countries. Moreover, a significantly higher cost of the device is responsible for lower demand in emerging and developed countries.


By Modality Analysis


Table-top Segment to Dominate Owing to Unique Characteristics of Portable Nebulizer Segment and its Convenient Use at Home  


On the basis of modality, the market is segmented into portable and table-top.


The table-top segment is expected to account for the largest share during the forecast period. Major factors contributing to the higher share of the segment include increase in the usage of table-top nebulizers due to the availability of reimbursement policies in developed markets, with operational benefits offered by these devices. For example, according to the U.S. Centers for Medicare and Medicaid Services (CMS), nebulizers are covered under the Durable Medical Equipment (DME) benefit by Medicaid. Also, the presence of a large number of players with a strong table-top device portfolio is contributing to the higher share of the segment in the market.


The portable nebulizer segment is anticipated to witness substantial growth during the forecast period. For instance, in November 2019, Drive DeVilbiss International announced the launch of the iGo2 Portable Oxygen Concentrator (POC), the first patented technology that automatically adjusts the dose of oxygen according to patients breathing rate. Distinct features offered by these devices, including the small device size making them easy to use at home, are likely to increase the demand for these devices during the forecast period. The growing number of players in developing portable devices and their rising adoption are likely to boost the portable segment growth during the forecast period significantly.


By End-user Analysis


Homecare Settings to Dominate Backed by Preferential Shift of Patients towards Medical Devices


The market is segmented into hospitals, clinics, and homecare settings in terms of end-user.


The hospitals segment dominated the global market in 2021. Higher demand for these devices from hospital settings, especially driven by the higher number of inpatient admissions with comorbid conditions, has been pivotal in higher demand for table-top and portable devices from these settings globally. For instance, according to the statistics published by GOV.UK, in June 2022, in England, the emergency admissions of children for bronchiolitis increased to 68.3% in 2021 compared to 60.8% in 2014.


The clinics segment has witnessed a lackluster demand for nebulizers, owing to the comparatively lower preference of patients toward receiving nebulization in clinics compared to hospitals. This factor is augmented by the shift of patients toward home settings, which has further limited the demand for these devices in clinics.


The shift of patients toward home settings and the introduction of new and portable devices, with comparatively lower costs have been pivotal in surging the demand for these devices from homecare settings.


REGIONAL INSIGHTS


North America Nebulizer Market Size, 2021 (USD Million)

To get more information on the regional analysis of this market, Request a Free sample


On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.


The market size in North America stood at USD 382.7 million in 2021 and is anticipated to continue to dominate the global market during the forecast period. A higher prevalence of asthma, other chronic respiratory conditions, and the rising adoption of advanced portable ones in the region have been instrumental in a higher market share of North America. According to the statistics published by the Asthma and Allergy Foundation of America in 2021, around 25.0 million people in the U.S. were living with asthma. Moreover, adequate reimbursement policies for these devices in the region are likely to boost the market growth in the region.


Europe is the second-most dominant region in terms of revenue and nebulizer market share. Primary reason attributed to the growth of the market in Europe is the rising prevalence of respiratory diseases, contributing to increasing demand for these devices in the Europe market. For instance, according to the statistics published by GOV.UK in 2021, 1.1 million hospital admissions of respiratory disorders were recorded in the U.K. Thus, the rising prevalence of respiratory diseases across the region is contributing to the growth of the segment.


The market in Asia Pacific is driven by the rising prevalence of chronic respiratory diseases, improving healthcare infrastructure and the growing number of medical device companies developing inhaled drug delivery devices to treat asthma and COPD. For example, in October 2020, HCmed Innovations Co., Ltd., announced the launch of Pulmogine in the China market. Also, in July 2021, HCmed Innovations Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for this product. The product is a vibrating mesh nebulizer equipped with Micro Synchronized Delivery Technology (MSDT).


On the other side, the market in Latin America and the Middle East & Africa is likely to grow at a slower pace. The rapid rise in the prevalence of asthma and COPD is likely to accelerate the demand for these devices for managing chronic respiratory diseases in the respective regions in the forthcoming years.


KEY INDUSTRY PLAYERS


Increasing Focus of Market Players on Innovations and Collaborations to Strengthen their Market Position


The global market is fragmented, with players, such as Omron Healthcare, Inc., Koninklijke Philips N.V., and PARI Respiratory Equipment, Inc. accounting for a significant share in 2021. The players focus on developing innovative devices and emphasize strategic partnerships and collaborations to strengthen their position in the market.



  • For instance, in March 2021, PARI Pharma GmbH received authorization for the LAMIRA nebulizer system to deliver ARIKAYCE (amikacin liposome inhalation suspension) in Japan. The system includes a customization medication reservoir that holds 8.4 ml dose and a specifically tailored aerosol head for aerosolization of ARIKAYCE with a valved aerosol chamber.

  • In March 2021, AireHealth collaborated with LucidAct Incto integrateLucidAct Provider Portal with AireHealth’s digital health solution to support remote management of chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions.


Moreover, the market is further characterized by many small manufacturers in emerging nations focusing on developing relatively lower-cost devices. Other key players offering a wide range of devices involve DeVilbiss Healthcare LLC, BRIGGS HEALTHCARE, GF HEALTH PRODUCTS, INC., Trudell Medical International, Allied Healthcare Products, Inc., Teleflex Medical, Inc., and others


LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • December 2021 – Aerogen collaborated with Nuance Pharma and entered into an agreement to develop a non-invasive approach for treating Respiratory Distress Syndrome (RDS). This agreement also grants Nuance to commercialize AeroFact, an innovative therapy that combines pulmonary surfactant drug with proprietary vibrating mesh technology.

  • July 2021 – PARI GmbH collaborated with TWT Digital Health (TWT) and developed the PARI Connect app. This app can be used to plan inhalations, take medications, or make doctor’s appointments and also enables the user to observe all the facts of their therapy. The app also communicates via Bluetooth with the eTrack controller, a control unit for PARI’s eFlow Technology nebulizer.

  • October 2020 – OMRON Healthcare, Inc. expanded the range of prescription-grade nebulizers. These systems are compact, quiet, and portable and provide greater ease to patients to manage asthma and chronic obstructive pulmonary disease (COPD).

  • July 2020 – OMRON Healthcare Inc., the leading Japanese player in home healthcare, announced the launch of OMRON NE C106. It is an addition to their compressor nebulizer portfolio. The company is continuously innovating in the area of respiratory medication delivery. 

  • April 2020 - Asclepius Meditec Co. Ltd., a China-based medical device company, announced the development of AMS-H-03, an advanced hydrogen-oxygen nebulizer to relieve the shortage of ventilators in China for the treatment of COVID-19 patients.


REPORT COVERAGE


An Infographic Representation of Nebulizers Market

To get information on various segments, share your queries with us



The global nebulizer market research report provides a detailed analysis of the market and focuses on key aspects such as technological advancements, the prevalence of asthma, and COPD. Besides this, the report offers insights into the market trends and highlights key industry developments such as mergers, partnerships, acquisitions, and the impact of COVID-19 on the market. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market's growth in recent years.


Report Scope & Segmentation






















































  ATTRIBUTE



  DETAILS



Study Period



2018-2029



Base Year



2021



Estimated Year



2022



Forecast Period



2022-2029



Historical Period



2018-2020



Unit



Value (USD million)



Segmentation



By Type, Modality, End-user, and Region



By Type




  • Jet Nebulizer

  • Ultrasonic Nebulizer

  • Mesh Nebulizer



By Modality




  • Portable

  • Table-top



By End-user




  • Hospitals

  • Clinics

  • Homecare Settings



By Geography




  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, Rest of Europe)



  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, Rest of Asia Pacific)



  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC Countries, Rest of the Middle East & Africa)



Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 833.6 million in 2021 and is projected to reach USD 1,202.5 million by 2029.

In 2021, North America stood at USD 382.7 million.

Registering a CAGR of 4.8%, the market will exhibit steady growth in the forecast period (2022-2029).

The jet nebulizer segment is expected to lead this market during the forecast period.

The rising incidence of chronic respiratory diseases, increasing adoption of homecare medical devices, and growing advancements in these devices are some key factors driving the market.

Omron Healthcare, Inc., Koninklijke Philips N.V., and PARI Respiratory Equipment, Inc. are among the top players in the market.

North America dominated the market in terms of share in 2021.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Oct, 2022
  • 2021
  • 2018-2020
  • 128

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X